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Policy Forum
P
neumonia is the single 
commonest cause of death 
in children under ﬁve years 
old, accounting for 2 million out 
of 10 million childhood deaths 
worldwide [1]. Severe pneumonia is 
an important diagnostic syndrome 
within the World Health Organization 
(WHO)/UNICEF system for 
triage and clinical management in 
developing countries, the Integrated 
Management of Childhood Illness 
(IMCI). The objective of IMCI is early 
recognition of disease and timely 
access to effective therapy; for severe 
pneumonia, this means referral to 
hospital and treatment with life-
saving antibiotics directed against the 
principal etiological agents, Streptococcus 
pneumoniae and Haemophilus inﬂuenzae 
type b (Hib) [2]. 
The Global Alliance on Vaccines 
and Immunization (GAVI) is 
now supporting introduction of 
conjugate Hib vaccine into routine 
childhood immunization programs 
in 24 developing countries [3], and 
introduction of 7-valent pneumococcal 
conjugate vaccine (PCV) will begin in 
three countries in 2008 [4]. As global 
coverage of these vaccines expands, the 
principal etiological causes of severe 
pneumonia will largely be controlled 
by immunization. The incidence of 
severe pneumonia and its attendant 
mortality may be reduced by 50% or 
more. If so, this will become a historic 
public health achievement and a 
pattern to emulate in other signiﬁcant 
infectious diseases of poverty. However, 
even if these highly effective vaccines 
reduce pneumonia mortality by half, 
residual deaths from pneumonia in 
childhood will still outnumber deaths 
from malaria [5]. A tremendous global 
health problem will remain. 
Furthermore, as much of our 
thinking about pneumonia is 
dominated by the two vaccine-
preventable pathogens, we will be 
poorly positioned to diagnose and 
manage these residual cases. In this 
policy discussion paper, we look to the 
future and imagine the implications of a 
successful vaccination campaign against 
H. inﬂuenzae type b and pneumococcus. 
Our assumption in doing so is that the 
burden of childhood pneumonia due 
to these infections will be dramatically 
reduced, and we discuss how such a 
reduction will inﬂuence the clinical 
diagnosis, classiﬁcation, management, 
and control of pneumonia. Although 
signiﬁcant global coverage of 10- or 13-
valent pneumococcal vaccines may be 
10–15 years ahead, the slow translation 
of ideas to research, policy, and then 
practice in developing countries 
suggests that we need to anticipate this 
scenario now.
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Summary Points
•  In developing countries, 
pneumococcus and H. inﬂuenzae 
type b are the dominant causes of 
severe pneumonia in children, and 
introduction of conjugate vaccines 
against these diseases could 
reduce the global burden of severe 
pneumonia by about half.
•  Present classiﬁcation and management 
guidelines for childhood pneumonia 
are founded on the dominance of 
these two organisms and will rapidly 
become obsolete as these vaccines are 
introduced.
•  The residual cases of pneumonia will 
have a wide variety of etiological 
causes and will include many cases 
of tuberculosis and noninfectious 
respiratory disease.
•  This broad etiological diversity will 
make the diagnosis, classiﬁcation, and 
management of pneumonia much 
more complex and expensive in future.
•  To be relevant to future policy, 
research in the areas of pneumonia 
diagnosis, classiﬁcation, prevention, 
or management should begin to 
anticipate this scenario now.
The Policy Forum allows health policy makers around 
the world to discuss challenges and opportunities for 
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1. Present Classiﬁcations of 
Pneumonia Will Become Obsolete
The World Health Organization 
pneumonia classiﬁcation system was 
designed to be used at ﬁrst point of 
contact, where a few reproducible 
signs could be elicited by health 
workers with only basic training. 
Bacteria account for the majority 
of fatal cases of pneumonia and, as 
treatment with antibiotics may be life-
saving and the adverse consequences 
of overtreatment are not signiﬁcant, 
the case deﬁnition emphasizes 
sensitivity over speciﬁcity. Thus, 
pneumonia is diagnosed simply by 
counting breaths per minute with 
different rate thresholds at different 
ages in children with a history of 
cough or difﬁculty breathing. Severe 
pneumonia is classiﬁed by the 
presence of lower chest wall indrawing 
and very severe pneumonia by signs of 
hypoxia or mental changes [6].
Pneumonia may also be classiﬁed by 
radiological patterns. Here again WHO 
has set standards in the interpretation 
of chest radiographs to minimize 
inter-observer variation in detecting 
alveolar consolidation or pleural 
effusion, both of which are strongly 
associated with bacterial etiology [7,8]. 
Hib vaccine was shown to reduce 
radiologically conﬁrmed pneumonia 
by approximately 20% among children 
in trials in The Gambia and Chile 
[9,10]. A 9-valent PCV prevented 37% 
of cases of radiologically conﬁrmed 
pneumonia among children in The 
Gambia who were already receiving 
Hib vaccine [11]. Combining these two 
protective effects from The Gambia 
suggests that radiologically conﬁrmed 
pneumonia would be reduced by 
50% following introduction of both 
vaccines. The effectiveness of each 
vaccine may be augmented further, in 
operational use, by herd protection 
[12,13], and the breadth of protection 
of PCV may also increase when 10- and 
13-valent vaccines become available 
over the next two to four years. The 
radiological classiﬁcation was designed 
primarily to evaluate vaccines against 
Hib and pneumococcal pneumonia 
and is not particularly sensitive to 
other etiologies. For example, in the 
Gambian trial of 9-valent PCV, only one 
third of placebo recipients with severe 
clinical pneumonia had radiographic 
appearances that satisﬁed the WHO 
criteria [11].
At present the WHO radiological 
deﬁnition beautifully illustrates the 
efﬁcacy of Hib and pneumococcal 
vaccines in trials, and the WHO clinical 
case deﬁnition sensitively captures 
patients with Hib and pneumococcal 
pneumonia for timely and effective 
antibiotic treatment. When these 
two diseases are controlled by 
vaccination, the rationale supporting 
both deﬁnitions will disappear. Little 
attention has been given to classifying 
the other etiologies of pneumonia, and 
in 10–15 years “other etiologies” will 
comprise almost all cases of pneumonia.
2. Present Case Management 
Strategies Will Become Outmoded
The WHO case management strategy, 
formulated in 1991, is rational and 
evidence-based [14]. A review of all 
etiology studies in developing countries 
using blood and lung aspirate cultures 
concluded that 55% of cases of 
hospitalized pneumonia were caused 
by bacteria, and approximately 70% 
of these cases were attributable to 
just two organisms, S. pneumoniae and 
H. inﬂuenzae type b [14]. Given the 
insensitivity of culture techniques 
[15], it is reasonable to assume 
that more than half of all cases are 
attributable to just two agents, and 
empiric treatment guidelines were 
designed to target these pathogens 
speciﬁcally. WHO supported a series 
of community-based controlled trials 
of this case management strategy, 
and in a meta-analysis of seven of 
these trials the estimated reduction 
in pneumonia mortality attributable 
to the intervention was 24% [16]. 
As WHO extended its empiric 
management guidelines to all the 
major syndromes of childhood, the 
pneumonia case management strategy 
became formalized within IMCI [2]. 
The two pathogens upon which the 
strategy is founded are precisely those 
whose decline we now anticipate. 
3. Causes of Pneumonia Will 
Become More Diverse
Beyond Hib and pneumococcus, the 
limited evidence we have from children 
2–59 months old suggests that the 
remaining pathogens are more equally 
distributed [17–23]. These include the 
bacteria Staphylococcus aureus, Moraxella 
catarrhalis, viridans group streptococci, 
Klebsiella pneumoniae, Escherichia coli, 
Acinetobacter species, non-typhi 
Salmonellae, Bordetella pertussis, non-
typeable H. inﬂuenzae, and Mycobacterium 
tuberculosis; the viruses RSV (respiratory 
syncytial virus), inﬂuenza A, inﬂuenza 
B, parainﬂuenza, adenovirus, human 
metapneumovirus, and rhinovirus; 
and the atypical organisms Mycoplasma 
pneumoniae, Chlamydia pneumoniae, 
and Chlamydia trachomatis. Pneumocystis 
jiroveci pneumonia (PCP) occurs 
primarily in immunosuppressed infants 
and children [23–25]. With a broad 
and even diversity of pathogens, the old 
strategy for empiric therapy of “picking 
the winners” may not have a signiﬁcant 
clinical impact. 
This diversity also reveals the 
impracticability of vaccination as the 
mode of further pneumonia control, 
except perhaps for RSV pneumonia. 
The beneﬁts of vaccination against H. 
inﬂuenzae type b and pneumococcus 
have been efﬁcient because of the 
simplicity of immunization and the 
dominance of the two pathogens; 
for the myriad of remaining causes 
of severe pneumonia, which cannot 
all be prevented by vaccination, 
devising effective diagnostic and 
case management strategies will be 
considerably more difﬁcult. By contrast, 
preventive strategies that act across 
a range of different etiologies, such 
as improving indoor air quality or 
preventing micronutrient deﬁciency, 
will appear relatively more efﬁcient in 
future.
4. Noninfectious Respiratory 
Disease Will Become More 
Prominent
The sensitive WHO clinical deﬁnitions 
of pneumonia encompass a wide 
variety of lung diseases, not all of which 
have the typical lung consolidation of 
pneumonia. Furthermore, etiology 
studies tend to overemphasize 
infectious causes of respiratory 
disease, and it is not until the lung 
is examined at post-mortem that 
the full breadth of noninfectious 
causes becomes apparent. Among 84 
HIV-negative children who died of 
respiratory disease in Zambia, half 
had acute pyogenic pneumonia at 
necropsy and 7% had PCP, while 18% 
had interstitial pneumonitis and 11% 
had pulmonary edema [24]. Anemia, 
malaria, congenital heart disease, acute 
interstitial pneumonitis, eosinophilic 
pneumonia (secondary to helminthiasis 
or schistosomiasis), and poisoning, PLoS Medicine  |  www.plosmedicine.org 0550 April 2008  |  Volume 5  |  Issue 4  |  e86
especially with kerosene [26], may all 
present with difﬁculty breathing or 
cough and a raised respiratory rate.
Unless the visual pattern of breathing 
is examined critically or an audible 
wheeze is sought in the breath sounds, 
asthma is easily misclassiﬁed as WHO-
deﬁned pneumonia [27]. As bacterial 
pneumonia declines in incidence, 
asthma will become relatively more 
prominent in the differential diagnosis 
of respiratory disease. Simultaneously 
with the increase in industrialization 
and urbanization in the developing 
world, the prevalence of asthma, 
bronchospasm, and atopy are also 
increasing in absolute terms [28,29]. 
The implications for health services are 
substantial: to distinguish asthma from 
pneumonia and provide appropriate 
therapy requires clinical training at 
a level much higher than is presently 
required for community- or primary 
care–level IMCI.
5. Tuberculosis Will Cause a 
Signiﬁcant Proportion of Severe 
Pneumonia
Among children with HIV infection, 
tuberculosis is a common cause of 
respiratory disease. For example, 
among 242 children admitted to 
hospital in Durban with WHO-deﬁned 
severe pneumonia, 38 (16%) had 
culture-proven tuberculosis and 
85% of these had a history of illness 
lasting less than two weeks [23]. In the 
necropsy study in Zambia, tuberculosis 
was diagnosed in 32 (18%) of 180 
HIV-infected children dying with 
respiratory disease [24]. In both these 
studies the prevalence of tuberculosis 
was equally high in HIV-uninfected 
children. If half of all present cases 
of severe pneumonia were prevented 
by antibacterial vaccines, tuberculosis 
would account for one third of 
future pneumonia cases in areas like 
these with a high prevalence of HIV. 
The insensitivity of diagnostic tests 
makes it difﬁcult to estimate the role 
and prominence of M. tuberculosis 
in childhood pneumonia, and a 
“trial of treatment” in patients who 
are unresponsive to penicillin or 
chloramphenicol is a blunt diagnostic 
tool with signiﬁcant toxic potential.
6. Antibiotic Therapy Will Become 
More Expensive
The decline of pneumococcus and Hib 
will raise two therapeutic problems. 
Firstly, if an antibiotic is required at 
all it will have to cover a signiﬁcant 
proportion of the bacteria listed above 
in section 3, which, in practice, suggests 
a third-generation cephalosporin, 
a macrolide, or a quinolone. These 
drug classes are substantially more 
expensive than the present developing 
world pharmacopoeia of benzyl 
penicillin, amoxicillin, gentamicin, 
and chloramphenicol. Although 
newer drugs are widely available 
in Asia, their cost is likely to create 
inequities in health care on a local 
scale and also between continents 
as they are less accessible in Africa. 
Furthermore, the potentially massive 
scale of their use in childhood 
pneumonia may lead to widespread 
antibiotic resistance, compromising the 
treatment of other important infectious 
diseases such as typhoid, bacterial 
meningitis, nosocomial infections, and 
tuberculosis. 
Secondly, there is little existing 
clinical evidence from developing 
countries to support the use of 
alternative antibiotics. For some of the 
causes listed, such as C. trachomatis, 
what evidence there is suggests that 
most patients recover without requiring 
antibiotics [30]. Antibiotic treatment 
is also superﬂuous for uncomplicated 
viral pneumonia. In a context where 
antibiotics are expensive and are 
actually required in only a minority of 
cases, a management algorithm that 
can focus this expensive resource on 
those who are likely to need it becomes 
an urgent priority. This will require a 
higher standard of clinical assessment 
than is presently available under IMCI 
and the implementation of follow-
up appointments in health systems, 
especially for those not receiving an 
antibiotic.
7. There Will Be Too Much 
Etiological Data, Not Too Little
In the past, microbiological studies 
have rarely deﬁned the etiology of 
more than two-thirds of all cases of 
pneumonia [17–20,22]. It is assumed 
that the undiagnosed fraction has 
roughly the same distribution of 
causes as the diagnosed fraction and 
that the division is accounted for by 
the poor sensitivity of the diagnostic 
assays used, such as blood cultures and 
complement ﬁxation tests. Molecular 
diagnostics, using multiplex PCR assays, 
MassTag PCR, and microarrays, will 
provide a wealth of data to re-evaluate 
this undiagnosed group [31–33]. 
However, existing studies, using 
traditional insensitive techniques, have 
frequently found evidence of two or 
more pathogenic agents within the 
same patient with pneumonia [17,23]. 
Highly sensitive molecular techniques 
are likely to lead to an explosion of 
“multiple etiologies.” Although the 
interaction between different agents 
in pneumonia pathogenesis is an 
interesting and convincing biological 
phenomenon, the likelihood is that the 
majority of agents identiﬁed in these 
patients will be either false laboratory 
positives or, more likely, false 
etiological positives—meaning that 
they are truly present but not involved 
critically in the development of disease. 
This tends to occur especially when the 
material under assay comes from the 
upper respiratory tract.
The new diagnostic tests will pose 
a considerable challenge to scientists 
working on pneumonia to evaluate 
causation through convincing 
observational and experimental 
designs. Identiﬁcation of the pathogen 
within lung tissue is more convincing 
than identiﬁcation in the nasopharynx. 
The absence of the pathogen in healthy 
controls or in subjects whose illness 
is conﬁned to the upper respiratory 
tract would add yet more conviction 
to the claim of causality. However, 
the most convincing evidence would 
come from focused intervention 
studies. Reduction of pneumonia in 
vaccine probe studies using inﬂuenza 
or RSV vaccines would permit an 
assessment of primary viral pneumonia 
and the role of viruses in secondary 
bacterial pneumonia. Alternatively, 
the additional effectiveness of broad 
spectrum antibiotics over present 
treatment standards in “undiagnosed” 
pneumonia would argue for a bacterial 
etiology.
8. Management of Pneumonia Will 
Be Determined by Risk Groups
Inevitably, without one or two 
dominant causes common to all types 
of patients, we will use the matrix 
of etiologies against patient and 
geographical risk factors to focus 
treatments to best effect. The single 
convenient and globally applicable 
treatment algorithm for “pneumonia” 
will be replaced by a complex branched 
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become apparent through further 
etiological studies, but some divisions 
are well established, and WHO has 
already differentiated its guidelines 
on treatment of HIV-positive and 
malnourished children. Pneumonia 
is more likely to be bacterial in young 
infants than it is in older children, and 
the causative bacteria are different; 
“adult” pneumococcal serotypes, 
which are not covered by present 
vaccines, group A streptococcus, group 
B streptococcus, and E. coli all occur 
with relatively greater frequency in the 
ﬁrst two months of life [34–36]. Gram-
negative bacteria are considerably 
more common among malnourished 
children than well-nourished children 
[19]. PCP, salmonellosis, and lymphoid 
interstitial pneumonitis are all more 
frequent among children with HIV 
[37]. In all children, contact with a 
case of tuberculosis may be a risk factor 
well worth determining. Nosocomial 
infections represent a large potential 
risk that has been little studied in 
developing world settings. Geography 
too may play a signiﬁcant part in the 
distribution of likely causes, separating 
for example Asia from Africa but also 
differentiating at country level. The 
prior probabilities of several etiologies, 
such as RSV, also vary considerably with 
season [38].
9. Ideal Point-of-Care Diagnostics 
Will Deﬁne Risk Factor 
Classiﬁcation
One solution to the changing 
epidemiology of pneumonia is 
the development of a new bedside 
diagnostic test using modern molecular 
technology. However, given the 
scenario envisaged above, the point-
of-care diagnostics that will be most 
useful in the speciﬁc management of 
pneumonia will be an HIV test with 
CD4 lymphocyte count, a generic 
marker of invasive bacterial disease, 
and a sensitive and rapid test for 
tuberculosis. Indications for supportive 
therapy are unlikely to change in the 
post-vaccine era and will rely heavily 
on the availability of oximetry to 
guide oxygen therapy. Radiographic 
classiﬁcation of respiratory disease 
has evolved little in the developing 
world, though many district hospitals 
that lack relatively basic tools are 
equipped with X-ray machines. There 
may be considerable additional gains 
in extending the WHO radiological 
classiﬁcation of pneumonia to deﬁne 
simple reproducible signs for lung 
disease caused by other etiologies.
Conclusion
It may seem rash even to contemplate 
the decline of S. pneumoniae, which 
has evolved as a varied, adaptable, 
and enduring human parasite. 
However, the operational success of 
PCV immunization in America does 
prompt this very consideration. If 
the initiative of the GAVI Alliance to 
introduce effective vaccines against Hib 
and pneumococcus throughout the 
developing world succeeds in reducing 
these diseases signiﬁcantly, our 
present approach to the management 
of pneumonia will abruptly become 
irrelevant. 
To prepare against this possibility, 
we need to re-examine thoroughly the 
broad clinical problem that is currently 
labeled “pneumonia”; that is, (i) to 
deﬁne and measure the causes of this 
collection of respiratory diseases; (ii) 
to determine the clinical, radiological, 
and laboratory features, or risk factors, 
that will differentiate these causes; (iii) 
to develop and validate appropriate 
tests to make this differentiation at 
ﬁrst and second referral level; (iv) to 
invest in community health systems 
and train health workers to recognize 
these more complex clinical patterns 
and use these new tests; (v) to estimate 
the effectiveness of treatments against 
the various causes through clinical 
trials which, by virtue of their focus 
on a subset of all cases of pneumonia, 
are likely to involve multiple sites; and 
(vi) to combine all these steps into a 
rational and appropriate management 
strategy within developing countries 
that also integrates attempts to reduce 
risk factors such as HIV infection, 
indoor air pollution, and poor 
nutrition. This represents at least 
a decade’s work, yet the situation 
we anticipate will arrive in many 
developing countries before a decade 
is out. “Early adopter” countries that 
introduce both vaccines into routine 
immunization in the next few years will 
provide useful settings in which to test 
research ideas. 
Despite dominating the childhood 
mortality tables throughout the 
developing world, severe pneumonia 
has received little scientiﬁc or public 
health attention for decades. The 
formation of a Global Action Plan 
for Pneumonia at WHO and the 
interest of public health foundations 
in supporting pneumonia research in 
developing countries are both welcome 
reversals of this longstanding neglect 
[39]. In the context of this renewal of 
interest, we argue that it is critically 
important to recognize the rapidity 
with which the target disease will 
change across the developing world 
and to anticipate in the research we 
propose today the very different clinical 
and epidemiological spectrum of 
pneumonia in the future.  
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